Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.

Kajosaari, Lauri I

Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. [electronic resource] - European journal of clinical pharmacology Mar 2006 - 217-23 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0031-6970

10.1007/s00228-005-0093-8 doi


Administration, Oral
Adult
Area Under Curve
Aryl Hydrocarbon Hydroxylases--antagonists & inhibitors
Blood Glucose--metabolism
Capsules
Carbamates--blood
Chromatography, Liquid--methods
Cross-Over Studies
Cytochrome P-450 CYP2C8
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme System--metabolism
Drug Administration Schedule
Enzyme Inhibitors--blood
Female
Gas Chromatography-Mass Spectrometry--methods
Half-Life
Humans
Hypoglycemic Agents--administration & dosage
In Vitro Techniques
Male
Pioglitazone
Piperidines--blood
Substrate Specificity
Thiazolidinediones--administration & dosage